Logo image of MRUS

MERUS NV (MRUS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MRUS - NL0011606264 - Common Stock

96.935 USD
-0.02 (-0.02%)
Last: 12/23/2025, 2:48:09 PM
Fundamental Rating

4

Taking everything into account, MRUS scores 4 out of 10 in our fundamental rating. MRUS was compared to 530 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MRUS as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, MRUS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MRUS has reported negative net income.
In the past year MRUS has reported a negative cash flow from operations.
In the past 5 years MRUS always reported negative net income.
MRUS had a negative operating cash flow in each of the past 5 years.
MRUS Yearly Net Income VS EBIT VS OCF VS FCFMRUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

The Return On Assets of MRUS (-42.15%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -49.18%, MRUS is in the better half of the industry, outperforming 65.85% of the companies in the same industry.
Industry RankSector Rank
ROA -42.15%
ROE -49.18%
ROIC N/A
ROA(3y)-32.12%
ROA(5y)-29.6%
ROE(3y)-43.27%
ROE(5y)-46.9%
ROIC(3y)N/A
ROIC(5y)N/A
MRUS Yearly ROA, ROE, ROICMRUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MRUS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRUS Yearly Profit, Operating, Gross MarginsMRUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

8

2. Health

2.1 Basic Checks

MRUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
MRUS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MRUS has been increased compared to 5 years ago.
MRUS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MRUS Yearly Shares OutstandingMRUS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
MRUS Yearly Total Debt VS Total AssetsMRUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

MRUS has an Altman-Z score of 31.60. This indicates that MRUS is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of MRUS (31.60) is better than 93.77% of its industry peers.
MRUS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 31.6
ROIC/WACCN/A
WACC7.43%
MRUS Yearly LT Debt VS Equity VS FCFMRUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

MRUS has a Current Ratio of 7.97. This indicates that MRUS is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 7.97, MRUS is doing good in the industry, outperforming 73.96% of the companies in the same industry.
A Quick Ratio of 7.97 indicates that MRUS has no problem at all paying its short term obligations.
MRUS has a Quick ratio of 7.97. This is in the better half of the industry: MRUS outperforms 73.96% of its industry peers.
Industry RankSector Rank
Current Ratio 7.97
Quick Ratio 7.97
MRUS Yearly Current Assets VS Current LiabilitesMRUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for MRUS have decreased strongly by -36.92% in the last year.
The Revenue has grown by 57.54% in the past year. This is a very strong growth!
The Revenue has been growing slightly by 3.03% on average over the past years.
EPS 1Y (TTM)-36.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.7%
Revenue 1Y (TTM)57.54%
Revenue growth 3Y-9.72%
Revenue growth 5Y3.03%
Sales Q2Q%3.21%

3.2 Future

MRUS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.57% yearly.
MRUS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 91.50% yearly.
EPS Next Y-75.87%
EPS Next 2Y-27.83%
EPS Next 3Y-11.15%
EPS Next 5Y29.57%
Revenue Next Year43.37%
Revenue Next 2Y17.82%
Revenue Next 3Y66.5%
Revenue Next 5Y91.5%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MRUS Yearly Revenue VS EstimatesMRUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
MRUS Yearly EPS VS EstimatesMRUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MRUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MRUS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRUS Price Earnings VS Forward Price EarningsMRUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRUS Per share dataMRUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

A cheap valuation may be justified as MRUS's earnings are expected to decrease with -11.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27.83%
EPS Next 3Y-11.15%

More info and screens

0

5. Dividend

5.1 Amount

MRUS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

MERUS NV

NASDAQ:MRUS (12/23/2025, 2:48:09 PM)

96.935

-0.02 (-0.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31 2025-10-31/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners91.6%
Inst Owner Change-3.84%
Ins Owners0.33%
Ins Owner Change-2.86%
Market Cap7.35B
Revenue(TTM)56.61M
Net Income(TTM)-381.13M
Analysts70.43
Price Target99.48 (2.63%)
Short Float %2.16%
Short Ratio0.94
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-36.37%
Min EPS beat(2)-83.38%
Max EPS beat(2)10.64%
EPS beat(4)2
Avg EPS beat(4)-12.3%
Min EPS beat(4)-83.38%
Max EPS beat(4)51.7%
EPS beat(8)3
Avg EPS beat(8)-15.65%
EPS beat(12)6
Avg EPS beat(12)-12.87%
EPS beat(16)10
Avg EPS beat(16)1.31%
Revenue beat(2)1
Avg Revenue beat(2)-0.47%
Min Revenue beat(2)-37.2%
Max Revenue beat(2)36.26%
Revenue beat(4)2
Avg Revenue beat(4)55.58%
Min Revenue beat(4)-37.2%
Max Revenue beat(4)232.22%
Revenue beat(8)3
Avg Revenue beat(8)27.5%
Revenue beat(12)6
Avg Revenue beat(12)19.96%
Revenue beat(16)9
Avg Revenue beat(16)16.38%
PT rev (1m)0%
PT rev (3m)6.56%
EPS NQ rev (1m)3.04%
EPS NQ rev (3m)1.87%
EPS NY rev (1m)1.54%
EPS NY rev (3m)4.18%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)-1.26%
Revenue NY rev (1m)2.14%
Revenue NY rev (3m)4.97%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 129.89
P/FCF N/A
P/OCF N/A
P/B 9.49
P/tB 9.51
EV/EBITDA N/A
EPS(TTM)-5.34
EYN/A
EPS(NY)-5.41
Fwd EYN/A
FCF(TTM)-4.19
FCFYN/A
OCF(TTM)-4.18
OCFYN/A
SpS0.75
BVpS10.22
TBVpS10.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.15%
ROE -49.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.12%
ROA(5y)-29.6%
ROE(3y)-43.27%
ROE(5y)-46.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.8%
Cap/Sales 1.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.97
Quick Ratio 7.97
Altman-Z 31.6
F-Score4
WACC7.43%
ROIC/WACCN/A
Cap/Depr(3y)275.9%
Cap/Depr(5y)195.01%
Cap/Sales(3y)10.83%
Cap/Sales(5y)7.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-36.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.7%
EPS Next Y-75.87%
EPS Next 2Y-27.83%
EPS Next 3Y-11.15%
EPS Next 5Y29.57%
Revenue 1Y (TTM)57.54%
Revenue growth 3Y-9.72%
Revenue growth 5Y3.03%
Sales Q2Q%3.21%
Revenue Next Year43.37%
Revenue Next 2Y17.82%
Revenue Next 3Y66.5%
Revenue Next 5Y91.5%
EBIT growth 1Y-60.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-39.36%
EBIT Next 3Y10.33%
EBIT Next 5YN/A
FCF growth 1Y-123.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-132.65%
OCF growth 3YN/A
OCF growth 5YN/A

MERUS NV / MRUS FAQ

Can you provide the ChartMill fundamental rating for MERUS NV?

ChartMill assigns a fundamental rating of 4 / 10 to MRUS.


Can you provide the valuation status for MERUS NV?

ChartMill assigns a valuation rating of 0 / 10 to MERUS NV (MRUS). This can be considered as Overvalued.


Can you provide the profitability details for MERUS NV?

MERUS NV (MRUS) has a profitability rating of 1 / 10.


Can you provide the financial health for MRUS stock?

The financial health rating of MERUS NV (MRUS) is 8 / 10.


What is the expected EPS growth for MERUS NV (MRUS) stock?

The Earnings per Share (EPS) of MERUS NV (MRUS) is expected to decline by -75.87% in the next year.